3 PhD positions in Hereditary & Early Onset Breast Cancer Epidemiology

TheNetherlands Cancer Institute (NKI) is recruiting three motivated and ambitious PhD students skilled in epidemiology biostatistics or computational biology to contribute to the Hereditary & Early Onset Breast Cancer: Comprehensive Personalized Assessment Early Risk Evaluation and Clinical Management (HER-CARE) project.

HER-CARE is a Marie Skłodowska-Curie Actions-Doctoral network that brings together 9 leading academic and 3 industrial partners to train a new generation of multidisciplinary researchers with the unified goal of advancing early onset and hereditary breast cancer research. In total the HER-CARE network will include 15 doctoral candidates across all participating addition to conducting your primary research you will broaden your experience through one international academic and one non-academic secondment within the HER-CARE network.

The network has three overarching aims:

1. to characterize spectrum of risk factors for early onset and hereditary breast cancer and its subtypes

2. to develop innovative approaches for risk stratification early detection and screening of invasive breast cancer and

3. to identify multi-modal markers of tumours and tumour environment to improve prediction of clinical outcomes and aid clinical decisions.

The Marjanka Schmidt Group is seeking PhD candidates for the following three projects within the network:

Risk and protective factors for the development of different subtypes of a second breast cancer (project 5):

Contralateral breast cancer is the most common second cancer in breast cancer survivors. Yet there is limited understanding of hereditary and non-hereditary risk factors for contralateral breast cancer hindering effective clinical management and informed personalized prevention strategies for breast cancer survivors. The doctoral candidate for this project will develop a multifactorial longitudinal database and perform statistical analyses to 1) identify novel factors influencing risk of second breast cancer including common and rare germline genetic variants immunological markers and mammographic density and 2) study the impact of different adjuvant treatment regimens used to treat a first breast cancer impact risk of a second breast cancer. The candidate will complete secondments at the University of Oxford (UK) and Evidencio (NL).

Risk modelling and online tool for shared decision making for risk management of second breast cancer (project 10):

Current risk models and clinical assessments are limited in their ability to distinguish which patients will develop contralateral breast cancer As a result women at low predicted risk may still opt for preventive surgeries such as contralateral mastectomy despite unclear survival benefits. The doctoral candidate will develop a multifactorial predictive model and online tool to assist in the shared decision-making of second breast cancer risk management along with a roadmap for its clinical implementation. Specifically the candidate will 1) upgrade the CanRisk tool for risk prediction of second breast cancers using the PredictCBC model 2) validate the upgraded CanRisk tool in relevant breast cancer populations including hereditary breast cancer survivors and 3) integrate CanRisk and PREDICT using the Evidencio platform for integrated second breast cancer risk assessment within context of prognostication of the first breast cancer. The candidate will complete secondments at the Cambridge Centre for Cancer Genetic Epidemiology (UK) and PHG Foundation (UK).

Genomic signatures of early onset tumours (project 12):

The distinct presentation and epidemiology of early-onset vs. late-onset breast cancer suggest biological differences between these tumours. However the genomic determinants of these differences have not been well characterized. The doctoral candidate will characterize the unique germline and tumour genetic profiles of early-onset breast cancer to uncover their biological origins improve detection and identify potential treatment targets tailored to distinct genomic and immunologic profiles. Specifically the doctoral candidate will use advanced statistical methods and programming tools (e.g. R Python) to integrate large-scale genomic histological and immunological data to identify the genomic contribution to breast cancer subtypes. The candidate will complete secondments at Centro Nacional de Análisis Genómico (Spain) and Methylomics (NL).

What are you going to do

• Conduct innovative interdisciplinary research to reveal novel insights about the aetiology progression and clinical management of early onset and hereditary breast cancer;

• Join the unique HER-CARE network that unites data-driven research with clinical translation to improve outcomes for women with hereditary and early-onset breast cancer;

• Actively collaborate with other researchers within the group the NKI and the HER-CARE doctoral network;

• Complete two secondments with both (inter)national academic collaborators and non-academic partners;

• Participate in five network-wide training events and consortium meetings;

• Present your (intermediate) research results at institutional meetings international conferences and workshops;

• Publish your results in peer-reviewed journals;

• Complete and defend a PhD thesis within the official appointment of four years.

If the challenge appeals to you and you recognize yourself in the conditions below we would like to invite you to apply. We are looking for colleagues who meets the following criteria:

• A MSc degree in epidemiology biostatistics bioinformatics computational biology or a related discipline (e.g. public health data science population genetics etc.);

• Prior experience (e.g. internship) in the field of cancer epidemiology is an asset;

• Fluent in academic English both spoken and written;

• Can work independently with a problem-solving attitude;

• Interdisciplinary oriented; curious and motivated to learn and apply concepts from various disciplines;

• Excellent social and communication skills and can work in collaboration with others in an international team.

Eligibility criteria

As part of the Marie Skłodowska-Curie Doctoral Network requirements the following eligibility criteria apply;

• Candidates can be of any nationality but candidates must not have resided or carried out their main activity (work studies etc.) in the Netherlands for more than 12 months in the 36 months immediately before their date of recruitment. Compulsory national service short stays such as holidays and time spent as part of a procedure for obtaining refugee status under the Geneva Convention are not taken into account. To demonstrate compliance candidates will be asked in a later stage of the procedure to complete a Mobility Declaration Form and provide supporting documents covering the 36 months prior to recruitment

• Candidates must not be in possession of a PhD degree

• Candidates must hold a Masters degree (or equivalent) before the start of the programme or by September 2026 at the latest tot be eligible for MSCA Doctoral Networks

Your development opportunities and employment conditions

The basis for your employment conditions is in accordance with theCLA Hospitals. You will receive from us:

• A temporary contract for four years for 36 hours per week (full time)

• A gross monthly salary between 3.665- and 4.450- based on a 36-hour working week in line with the OIO scale and depending on your experience;

• 144 holiday hours and 57 hours of Personal Life Budget with full-time employment

• Annual holiday pay of 8.33% and a fixed end-of-year bonus of 8.33%

• A travel allowance of 0.23 per km

• Free parking at the Netherlands Cancer Institute. And with our bicycle plan and discount on public transport we also make it attractive for you to leave the car at home

• An environment where you can continue to learn and develop your personal and professional skills

• An active PhD council

• A cutting-edge dynamic and international research environment

• Opportunities to collaborate with scientists in different disciplines

Interested

Are you interested in these projects curious and motivated to impact cancer research and clinical care We are eager to meet you! You can apply by clicking the apply/solliciteer button at the top of the page. Include in your application:

• Motivation letter explaining why you are excited about the project and what experience and personal qualities make you a strong candidate.

• CV including your MSc grades and publications (if any). If you dont have a MSc certificate yet explain briefly what you still need to complete and provide your expected graduation date. Your CV should also include the contact details of two references (name email address phone number).

Please ensure that your CV the overview of your grades and your references are submitted as one document as there is no option to submit them separately.

These vacancies are open for applications until December 31 2025. We will contact qualified candidates in January to invite them for an interview. The first interview round will be scheduled onand 30 January. The second interview round will take place between 3 and 5 February.

For questions about the positions please contact us at .

Why the Netherlands Cancer Institute

The Netherlands Cancer Institute (NKI) is a dynamic comprehensive cancer center accommodating over 55 research groups and many state-of-the-art core facilities including imaging flow cytometry proteomics genomics and screening. At the Netherlands Cancer Institute we have a shared goal: providing the best care for every patient and every type of cancer. Quite a lot but not impossible. Here science and health care join forces towards innovation. We keep finding new ways to help people facing cancer on a global scale.

About the Group

The Schmidt Group is a vibrant and international group of PhD students postdocs and scientists working to investigate genetic physiological and clinical factors that contribute to development detection and treatment of first and second breast cancers. As a group we have the overarching goals to prevent breast cancer and recurrence of cancer improve early detection and reduce overtreatment. Additionally we study and aim to implement the best Ethical Legal and Societal (ELSI) practices related to the (secondary) use of human data and materials for clinical research. Our group is positioned within the Division of Molecular Pathology where we work side by side with fundamental translational and clinical research groups.